A developer of synthetic antibodies for inflammatory and skin disorders is becoming a public company through a special purpose acquisition-merger. . . . → Read More: Synthetic Antibody Company Goes Public in $230M Merger
|
|||||
       
  |
 Comments are closed  Finance  biomedical, biotechnology, clinical trials, entrepreneurs, equity, Europe, investment, IPO, merger, pharmaceuticals 
A company producing synthetic RNA for agricultural and biomedical applications is now a public company after a special-purpose acquisition. . . . → Read More: RNA Manufacturer Goes Public in $282M Merger Comments are closed Finance agriculture, biomedical, biotechnology, chemistry, Covid-19, entrepreneurs, equity, investment, IPO, life sciences, manufacturing, merger, physical sciences 
A company developing synthetic biology and engineering tools for biotechnology is becoming a public company through a special-purpose acquisition. . . . → Read More: Synthetic Bio Company Goes Public in $2.5B Merger Comments are closed Finance biotechnology, economics, engineering, entrepreneurs, equity, genomics, investment, IPO, life sciences, merger, pharmaceuticals 
Zymergen Inc., a developer of materials made with synthetic biology for industrial products is raising $500 million in its initial public stock offering. . . . → Read More: Biomanufacturing Materials Company Issues $500M IPO One comment - (Comments are closed) Finance agriculture, biotechnology, chemistry, economics, engineering, equity, genomics, investment, IPO, life sciences, manufacturing, materials science, mathematics, physical sciences 
A company developing regenerative therapies with engineered stem cells for cancer and other diseases is raising $587.5 million in its initial public offering or IPO. . . . → Read More: Engineered Cell Therapy Company Issues $588M IPO One comment - (Comments are closed) Finance biomedical, biotechnology, equity, genomics, investment, IPO, life sciences, pharmaceuticals, preclinical, stem cells, university 
Total venture investments in dollars jumped to a new high in the U.S., while biotechnology remained the single hottest sector in 2020. . . . → Read More: 2020 Venture Funds Mixed, Biotech Keeps Sizzling One comment - (Comments are closed) Finance biotechnology, economics, equity, investment, IPO, merger, software, venture capital
A biotechnology company developing therapeutic antibodies for Covid-19 infections is raising $483 million in its initial public offering of common stock. . . . → Read More: Covid-19 Antibody Developer Raises $483M in IPO One comment - (Comments are closed) Finance biomedical, biotechnology, Canada, clinical trials, Covid-19, equity, FDA, investment, IPO, NIH, pharmaceuticals 
Nationwide jitters in the U.S. appear to be affecting venture capital activities in the week of the presidential and congressional elections. . . . → Read More: Venture Rounds, IPOs, Mergers Vanish in Election Week One comment - (Comments are closed) Finance economics, entrepreneurs, equity, investment, IPO, merger, statistics, venture capital
A company developing a treatment for Covid-19 infections taken as a tablet instead of infusion issued its initial public offering, or IPO, for common stock. . . . → Read More: Covid-19 Drug Biotech Raises $300M in IPO Comments are closed Finance biomedical, biotechnology, clinical trials, Covid-19, equity, investment, IPO, licensing, life sciences, pharmaceuticals
A company developing a drug for depression based on synthesized compounds in hallucinogenic substances is raising $127.5 million in its initial public stock offer. . . . → Read More: Mental Health Drug Company Raises $127.5M in IPO Comments are closed Finance biomedical, clinical trials, entrepreneurs, equity, investment, IPO, life sciences, pharmaceuticals, psychiatric, U.K. |
|
|||
|
Copyright © 2021 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |
|||||
